Objective: Knowledge is limited about the standardised instruments used to collect resource use and quality of life data alongside trials of dementia interventions. This review aimed to identify the trials using such instruments in order to guide the design of future trial-based cost-effectiveness studies.
| INTRODUCTION
Dementia is a growing public health problem, 1 and the worldwide cost of dementia has been estimated to exceed those of other chronic diseases. 2 Some new treatments have been developed, which could contribute to the care of people with dementia and their families in a wide range of domains. 3 Given the finite health care budget, economic evaluations aiming to support decision making about these new treatments in dementia are essential. Ideally, these evaluations should be based on long-term clinical trial results that capture the benefits and costs of the intervention. 4 Cost-utility analysis is the most widely used form of economic evaluation. In such analysis, quality-adjusted life year (QALY) is routinely used as the summary measure of health outcomes, which takes both the quantity and quality of life into account. In dementia research, Quality of Life (QoL) has been recognised as an important measure as the clinical measures. Several instruments have specifically been developed to assess QoL in dementia. 1, 5 According to the most recent systematic review, 5 more than 10 QoL measures were identified and properties assessed, but this review was limited to disease- 7 instruments are recommended for cost data collection to improve the quality and uniformity of data generated from trials. But it is not practical to have standardised instruments to measure costs because the range of services to be costed in an economic evaluation depends a lot on the type of intervention and the data sources available. To address this issue, some investigators use questionnaires that could be tailored to meet the needs of each individual study. A frequently used questionnaire is the client service receipt inventory (CSRI), and it has been widely used and adapted to collect data in some observational studies in dementia. 8 Alternatively, there is one standardised and dementia-specific tool available to collect resource use data, Resource Utilisation in Dementia (RUD) instrument. 9 It has been used in clinical drug trials and observational studies. 10, 11 But there is a lack of information about the use of RUD in clinical trials, especially for non-pharmacological interventions, and whether there are other instruments available to collect resource use data in such trials is yet unknown.
Therefore, this review aimed to identify the trials using resource use and QoL measures to collect data in clinical trials about dementia or cognitive interventions and then describe and compare these instruments in terms of their performance in trials, in order to provide a foundation for the study design of future clinical trial-based costutility analysis of dementia or cognitive interventions.
| METHODS
In accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) Statement 12 (see Appendix S1), this review followed the published protocol 13 and consisted of acquiring, extracting, and assessing the data ( Figure 1 ).
| Eligibility criteria
The eligibility criteria were:
• Population-older adults with dementia or cognitive impairment
• Intervention-all types of interventions, both drug and nondrug therapies
• Comparator-no intervention or the usual care
• Outcomes-measurement and reporting of QoL, or resource use or both
• Study type-randomised clinical trial (RCT), or feasibility study or pilot study
The definition of "older patients with dementia or cognitive impairment" used in this review was based on each individual study if it described its population as being old adults with dementia or cognitive impairment. Quality of life is an abstract and broad concept including physical function, perceptions of well-being, satisfaction, and sense of self-worth. It has to be assessed by using questionnaires to survey the relevant subjects. Both the profile-based and preference-based QoL instruments were eligible for this review. An instrument is profile-based if it measures different domains of health-related QoL and generates a score for each of these domains, eg, 36-item Short-Form (SF-36). If an instrument measures the utility of certain health outcomes, the instrument is preference-based, eg, the EuroQol 5-dimension (EQ-5D), 14 which could provide a single overall health utility score for QALYs calculation. Given the aim of this review was to guide cost-utility analysis study design, health utility, quality-adjusted life years, and QALYs were also used as the search terms. We included RCT or pilot/feasibility studies using RCT design, which were small-scale preliminary studies conducted prior to the full RCTs in order to evaluate feasibility, effects, etc.
| Search strategy
The following major databases (Ovid Medline, PsycINFO, EMBASE, CINAHL, Cochrane Databases of Systematic Reviews, Web of Science, and Scopus) were searched in September 2016, and the searches were re-run before the final analyses in June 2017. A hand search of the references of included articles and general search, eg, Google Scholar, were also conducted to identify potential relevant studies. Key terms were determined through discussion between authors. The search strategies were created specifically for each database using relevant index and free text terms (see Appendix S2 for the terms used in Ovid Medline). Studies were eligible regardless of the language or date of publication, but the abstract was available in English.
| Article selection
All results were exported into Endnote X7 software (Thomson Reuters, 2016 
KEY POINTS
• Economic evaluations of dementia interventions are essential to assess the cost-effectiveness, and, ideally, these evaluations would be based on clinical trial results that capture both benefits and costs over the long-term.
• Standardised instruments are recommended to collect such data alongside trials, but this knowledge is limited.
• Several useful instruments were identified, including CSRI for resource use, DEMQOL, SF-12, and EQ-5D-5L for quality of life data. These instruments would contribute to future economic evaluation alongside clinical trials in dementia care.
Discrepancies were resolved through discussion or adjudication by a third author (P.D.) if necessary.
| Data extraction
We developed a standardised excel sheet to extract data from the included studies, including publication characteristics, participant characteristics, intervention characteristics, and instrument characteristics.
| Data synthesis
First, the characteristics of included studies were tabulated. Second, we summarised the frequency of each instrument used in the trials. Third, the characteristics of each QoL instrument were described and tabulated, using a table adapted from the one used in a review of dementia-specific QoL scales, 5 including instrument, conceptual basis, patient/proxy report, patient population, subscales, items, response options, and scoring.
3 | RESULTS
| Search results
The searches yielded 2527 records. After removing duplicates, the title and abstract of 1089 unique records were screened. Sixty-five were sought for full-text screening, and 41 studies were eligible for inclusion.
| Study characteristics
The studies were published between 2000 and 2017 and conducted in 15 countries/regions, most frequently in the US, the UK, and Australia ( care survey, and a study-specific questionnaire developed specifically for that study.
| Client Service Receipt Inventory (CSRI)
There were 5 studies using adapted CSRI to collect resource use data. [15] [16] [17] [18] [19] [20] [21] All studies were conducted in the UK, ranging from mild to severe dementia. The CSRI was developed by Knapp 
| Resource Use Inventory (RUI)
In the Finnish study for people with mild cognitive impairment, 23 utilisation of health resources was estimated using register data and questionnaire data. The questionnaire used in this study was the Resource Use Inventory (RUI), 24 which was developed to capture resource utilisation and costs in populations with Alzheimer 0 s disease.
The RUI was completed by the patient and the carer together. It consisted of 9 questions to document the use of direct medical services and nonmedical care. The RUI also includes questions to capture the time caregivers spend providing care to the patients and the time use of the patients by participating in paid and volunteer work.
| Cost diary and survey
In a study for Dutch dementia patients, 25 resource use data were estimated using the hospital and pharmacy datasets, the informal care surveys, and cost diaries. The informal care survey was developed by van den Berg et al for the measurement and valuation of informal care. 26 In this survey, informal caregivers were asked to indicate the average time spent on different informal care tasks per week, at baseline and at follow-ups. The carers were also asked to complete the cost diaries at both baseline and follow-ups to determine the costs made outside the hospital that could not be gathered from the hospital or pharmacist 0 s registrations. Cost diaries are an accepted method to assess resource use in cost-effectiveness studies. 27 
| Study-specific questionnaire
In the cost-benefit analysis of drug therapies for outpatients with Alzheimer 0 s disease done in US, 28 a questionnaire was developed for this study and was completed by the caregiver every month to document the health care service use, including hospital stays, outpatient services, community supports, and other related services.
| QoL measure
The quality of life was assessed using a wide range of instruments across the studies (Table 2) . We noted 15 different QoL instruments, with 5 dementia-specific and 10 generic. Multiple measures were used in several studies.
| Dementia-specific measure
The dementia-specific instruments identified were: Quality of Life in (n = 2), and Dementia Quality of Life Instrument (DQOL) (n = 1). The characteristics of these instruments were summarised in Table 3 . 
Quality of Life in Alzheimer

Dementia Quality of Life questionnaire (DEMQOL)
The DEMQOL is a 28-item instrument, which covers 5 domains of quality of life (daily activities and looking after self; health and wellbeing; cognitive functioning; social relationships; self-concept), aiming to assess QoL in people with mild to moderate dementia. 6 A proxy version was developed for caregivers, DEMQOL-Proxy, with 31 items.
A 4-point Likert scale (a lot/quite a bit/a little/not at all) is used to collect responses to each item. A Likert scale measures attitudes and behaviours using answer choices that range from one extreme to another and thus allows the respondent to uncover degrees of opinion.
In the eligible studies, DEMQOL and DEMQOL-Proxy were used together with the exception of DEMQOL-Proxy for people with moderate to severe dementia. 18 Score ranges from 28 to 112 for DEMQOL and 31 to 124 for DEMQOL-Proxy. Higher scores indicate better QoL.
In addition, health utility values can be generated from DEMQOL (DEMQOL-U) and DEMQOL-Proxy (DEMQOL-Proxy-U) to enable the QALYs calculation for cost-utility analysis. 30 This approach has been used in the economic evaluation study of a maintenance cognitive stimulation therapy for people with mild-to-moderate dementia in the UK. aesthetics, positive affect, absence of negative affect, belonging, and self-esteem. 33 It was developed through literature review and consultation with expert panels composed of dementia patients, caregivers, and professional care providers. 34 Items are rated on one of two 5-point Likert scales (ranging from not at all to a lot, and never to very often) and DQOL yields scores on 5 subscales. Lower scores on "negative affect" and higher scores on other subscales indicate worse QoL. 
| Generic QoL measure
EuroQol 5-dimension (EQ-5D)
The EQ-5D is a generic, utility-based QoL instrument. It can be simply administered to patients in the form of a self-completed questionnaire.
All the identified studies used the 3-level version (EQ-5D-3L), which consists of 5 domains (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) and 3 levels for each domain (no problems/some problems/extreme problems or unable). According to the domains and levels, EQ-5D-3L yields 243 potential health states, each of which is assigned a utility weight, range from −0.594 to 1 using a utility scoring function derived from the UK general population. High scores represent higher utility. Among the 5 studies using EQ-5D as an outcome measure, 3 studies included both self-rated and proxy-rated EQ-5D. 16, 20, 35 The EQ-5D is recommended by the National Institution for Health and Care Excellence (NICE) in England to be used in economic evaluations of health care interventions. 36 
15-dimension (15D)
15D is a generic health utility QoL measure. 37 It consists of 15 dimensions (mobility, vision, hearing, breathing, sleeping, eating, speech, excretion, usual activities, mental function, discomfort and symptoms, depression, distress, vitality, and sexual activity) with 5 ordinal levels.
Similar to EQ-5D, a single index score measure can be calculated from the health state descriptive system by using a set of utility weights.
The index score ranges from 0 to 1. 37 The 15D scores have been shown to be reliable, sensitive and responsive to change, and valid for deriving QALYs. 37 In the identified study, 22 it was measured directly from the participants, who were at risk of cognitive decline.
Health Utilities Index Mark 3 (HUI3)
HUI3 is also a generic health utility measure consisting of 8 attributes:
hearing, vision, speech, ambulation, dexterity, emotion, cognition, and pain. Each attribute has multiple functioning levels. To calculate the HUI3 score, a utility scoring function derived from a representative sample of the Canadian general population is used. Score ranges from −0.36 to 1 with higher scores reflecting better health. 38 In the study about dementia interventions, 28 HUI3 was administered to caregivers to rate patients 0 QoL, supplemented by several disease-specific measures. it has been used increasingly because of its lower burden to respondents and similar measurement properties as its longer version. 39 In the trials identified, 23, 40, 41 both instruments were used to collect data from patients with mild cognitive impairment directly at baseline and follow-ups.
12-item General Health Questionnaire (GHQ-12)
GHQ-12 measures 2 main areas with 12 items: the inability to carry out normal functions and the appearance of new and distressing phenomena. In the study identified from this review, 42 GHQ-12 was used to ask patient to rate their own QoL. The score ranges from 0 to 36 with lower scores indicating better health.
15-item Quality of Life Scales (QOLS)
QOLS has 15 items that measures 5 domains of life: material and physical well-being; relationships with other people; social, community, and civic activities; personal development and fulfilment; and recreation. 43 The QOLS scores range from 16 to 112 with higher scores indicating better quality of life. 43 It was used to collect data from individuals with mild cognitive impairment directly. 40 Anamnestic comparative self-assessment scale (ACSA)
ACSA is a 10-stage anchor scale for a global assessment of present quality of life defined in terms of the "best time" versus the "worst time" in life. A higher quality of life is reflected by an improvement in the global scale score. It was completed by the patients themselves at both baseline and follow-up. 44 QOL face scale QOL Face Scale is a 9-choice picture format with a score range of 1-9
(worst = 1, best = 9, from frowning to smiling faces) assessing the degree of general happiness in current daily life. It was used to ask the caregivers to answer these questions on behalf of the patients with dementia. 45 Quality of Life Assessment-Patient (QLA-P)
QLA-P is a rating scale completed by caregivers to assess broad areas of patient 0 s quality of life. The original version includes 10 categories (working, leisure, eating, sleeping, social contact, earning, parenting, loving, environment, and self-acceptance). In the identified study, 46 the scale was adapted to increase its relevance to patients with e172Alzheimer 0 s disease. Each category is rated using an anchor points (0 and 50), with higher scores reflecting higher QoL.
| DISCUSSION
In view of the need for economic assessment of dementia interventions, collecting information on resource use and quality of life using the standardised instruments in clinical trials is important to ensure high quality data for further cost-effectiveness analysis. In this review, we examined 41 studies to identify such instruments used in dementia.
The resource use instruments were seldom used in previous is the scale developed exclusively to be administered to patients 49 and assesses feeling states and mood, which may fail to capture other QoL areas impact by the disease. Based on the conceptual framework and applicability, QOL-AD and DEMQOL are preferred in future trials of people with mild to moderate dementia, but if the study focuses more about health-related QoL, DEMQOL may be a better choice. Furthermore, as described previously, health utility scores, DEMQOL-Utility, can be generated from DEMQOL, which could be used to complement the generic utility instrument in future cost-utility analysis, 30 although its validity and responsiveness need further testing.
Regarding the generic QoL measure, we identified 3 instruments that generate health utility scores and 7 other measures. EQ-5D is the most used health utility instrument, but it has been commented to lack sensitivity, especially in the area of mental health. 50 Therefore, the 5-level EQ-5D (EQ-5D-5L) is suggested to be used because of its improved sensitivity and reduced ceiling effect. SF-36 and SF-12 are the mostly used generic QoL instruments, providing summary scores of health-related QoL and thus enabling comparisons across different diseases, population groups, and interventions. 51 Although SF-36/ SF-12 is increasingly used in patients undergoing routine operations, it may fail to observe the small but clinical important differences or changes in dementia study, which could be captured by diseasespecific measures. Preferences for generic or disease-specific measures usually depend on the purpose of the study 51 ; therefore, if a study aims not only to measure the QoL concepts covered by a generic measure, but also to capture the specific concerns related to dementia or cognitive impairment, we suggest to include both generic and dementia-specific measures in the same study.
It should be noted that in previous trials in mild to moderate dementia, 15, 16 both DEMQOL and DEMQOL-Proxy were included.
Self-rated and proxy-rated EQ-5D were also used together in several studies. 16, 20, 35 Given the complexity of dementia, researchers suggest that both patient-reported outcomes and observable behaviour, which is based on proxy-reporting, should be included in order to better measure the effects of interventions. 30 DEMQOL-Proxy has been
shown to give complementary perspectives on QoL to DEMQOL, 6 and thus the use of both measures together is recommended. What is more, at some point, patients may be unable to meaningfully assess their own QoL, and under such circumstances, researchers have to rely on other sources such as proxy-reporting. Proxy EQ-5D appears to be an acceptable source of data for QALYs 52 and has been used in some studies. But due to the poor agreement between proxy scores and selfreported scores, they cannot be assumed to substitute for each other, 53 and cost-effectiveness analyses using both approaches should be conducted.
The limitation of this review should be mentioned. Because no quality assessment tool was available for this kind of review and the psychometric properties were not formally compared in this review, our approach necessarily involved subjective judgement.
| CONCLUSIONS
There is a lack of firm evidence about the use of standardised instrument to collect resource use and QoL data in trials about interventions for dementia. Several useful resource use and quality of life measurement instruments have been identified by this review, which would contribute to the study design of future economic evaluation alongside clinical trials in dementia care. For resource use, CSRI was mostly used, but no studies have used RUD; for QoL, we recommend the inclusion of dementia-specific DEMQOL, generic SF-12, and health utility EQ-5D-5L, based on both self-report and proxyreport.
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